TY - JOUR
T1 - Belimumab for systemic lupus erythematosus–Focus on lupus nephritis
AU - Plüß, Marlene
AU - Piantoni, Silvia
AU - Tampe, Björn
AU - Kim, Alfred H.J.
AU - Korsten, Peter
N1 - Funding Information:
M.P. reports no conflicts of interest. S.P. has received honoraria or travel support from Abbvie, Astra Zeneca, Bristol-Myers-Squibb, Galapagos, Janssen-Cilag, and Pfizer, all unrelated to this paper. B.T. reports no conflicts of interest. A.H.J.K. participated in consulting, advisory board, or speaker’s bureau for Alexion Pharmaceuticals, AstraZeneca, Aurinia Pharmaceuticals, Exagen Diagnostics, Inc., GlaxoSmithKline, and Pfizer and received funding under a sponsored research agreement unrelated to this review from GlaxoSmithKline and Foghorn Therapeutics. P.K. has received honoraria or travel support from Abbvie, Amgen, Biogen, Boehringer Ingelheim, Bristol-Myers-Squibb, Chugai, Gilead, GlaxoSmithKline, Janssen-Cilag, Lilly, Pfizer, and Sanofi-Aventis, all unrelated to this paper. P.K. received research grants from GlaxoSmithKline and Diamed Medizintechnik GmbH, unrelated to this paper. P.K. also discloses his participation as an investigator in the BLISS-LN trial. GlaxoSmithKline, the manufacturer of belimumab, had no role in the conceptualization, data acquisition, data interpretation, or writing of this paper.
Publisher Copyright:
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN.
AB - In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN.
KW - Systemic lupus erythematosus
KW - belimumab
KW - immunosuppressives
KW - lupus nephritis
UR - http://www.scopus.com/inward/record.url?scp=85130972053&partnerID=8YFLogxK
U2 - 10.1080/21645515.2022.2072143
DO - 10.1080/21645515.2022.2072143
M3 - Review article
C2 - 35588699
AN - SCOPUS:85130972053
SN - 2164-5515
VL - 18
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 5
M1 - 2072143
ER -